Vita Genomics and ITRI to Market Each Other's PGx Tools to Pharmas | GenomeWeb
NEW YORK (GenomeWeb News) — The Industrial Technology Research Institute and Vita Genomics will market their pharmacogenomics services to drug developers, Vita said today.
 
Under the agreement, the companies plan to offer Vita’s high-throughput sequencing, genotyping, and gene-expression profiling, and ITRI’s proteomics databases to pharmaceutical companies.
 
Both shops are based in Taiwan. Vita has a marketing operation in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.